Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Gynecol Oncol. 2013 Dec;131(3):551-4. doi: 10.1016/j.ygyno.2013.08.016. Epub 2013 Sep 2.
To evaluate the clinical significance of fertility-preserving comprehensive staging surgery (CSS) in the treatment of malignant ovarian germ cell tumors (MOGCTs).
A total of 92 cases of MOGCTs were retrospectively reviewed.
Forty-six patients (50%) received CSS, which includes ipsilateral adnexectomy+omentectomy+retroperitoneal lymphadenectomy (appendectomy and multiple biopsies as required). Forty-six patients (50%) received USO, which includes ipsilateral adnexectomy+clinical intraoperative evaluation (including retroperitoneal lymph nodes, great omentum, peritoneal, and contralateral ovary), biopsy of suspicious sites, and excision of all visible lesions. The mean operation time (177.0 vs. 114.8 min; p<0.0001) and the mean intraoperative blood loss (499.1 ml vs. 112.9 ml; p=0.04) were significantly higher in the CSS group compared to those in the USO group. The complication rate (17.4% vs 0%, p=0.003), the relapse rate (10.9% vs 2.2%, p=0.102) and the mortality rate (4.3% vs 2.2%, p=0.500) were higher in the CSS group compared to those in the USO group. The difference in complication rate was statistically significant. The overall 5 year survival rates were 92% and 97% in the CSS and USO groups, respectively (p=0.575). Tumor-free survival rates at 5 years were 87% and 97% in the CSS and USO groups, respectively (p=0.115).
The benefit of fertility-preserving CSS to MOGCT patients was not greater than that of USO. It is safer and more effective to perform ipsilateral adnexectomy+clinical intraoperative exploration surgery (including retroperitoneal lymph nodes, great omentum, peritoneal, and contralateral ovary), biopsy of suspicious sites, excision of all visible lesions, and adjuvant chemotherapy.
评估保留生育功能的全面分期手术(CSS)在治疗恶性卵巢生殖细胞肿瘤(MOGCTs)中的临床意义。
回顾性分析 92 例 MOGCTs 患者的临床资料。
46 例(50%)患者接受 CSS,包括同侧附件切除术+大网膜切除术+腹膜后淋巴结切除术(根据需要进行阑尾切除术和多处活检)。46 例(50%)患者接受 USO,包括同侧附件切除术+临床术中评估(包括腹膜后淋巴结、大网膜、腹膜和对侧卵巢)、可疑部位活检和切除所有可见病变。CSS 组的平均手术时间(177.0 分钟 vs. 114.8 分钟;p<0.0001)和术中平均出血量(499.1 毫升 vs. 112.9 毫升;p=0.04)显著高于 USO 组。CSS 组的并发症发生率(17.4% vs. 0%,p=0.003)、复发率(10.9% vs. 2.2%,p=0.102)和死亡率(4.3% vs. 2.2%,p=0.500)均高于 USO 组。并发症发生率的差异具有统计学意义。CSS 组和 USO 组的 5 年总生存率分别为 92%和 97%(p=0.575)。CSS 组和 USO 组的 5 年无瘤生存率分别为 87%和 97%(p=0.115)。
与 USO 相比,保留生育功能的 CSS 对 MOGCT 患者的获益并不更大。行同侧附件切除术+临床术中探查术(包括腹膜后淋巴结、大网膜、腹膜和对侧卵巢)、可疑部位活检、切除所有可见病变、辅助化疗更安全、更有效。